^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GNOS-PV01

    i
    Other names: GNOS-PV01
    Associations

    News

    Trials
    Company:
    Geneos Therap
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    12ms
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Washington University School of Medicine | Trial completion date: Apr 2023 --> Dec 2023
    Trial completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    over1year
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Apr 2023 | Trial primary completion date: Dec 2023 --> May 2022
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    almost2years
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Washington University School of Medicine | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    almost2years
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Washington University School of Medicine | Trial completion date: Jul 2023 --> Nov 2023 | Trial primary completion date: Aug 2022 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    over2years
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Washington University School of Medicine | Trial completion date: Jul 2024 --> Jul 2023 | Trial primary completion date: Oct 2023 --> Aug 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    almost4years
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=6, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    almost4years
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Washington University School of Medicine | Trial completion date: Apr 2024 --> Aug 2024 | Initiation date: Apr 2020 --> Aug 2020 | Trial primary completion date: Jul 2023 --> Nov 2023
    Clinical • Trial completion date • Trial initiation date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
    4years
    Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Washington University School of Medicine | Trial completion date: Dec 2023 --> Mar 2024 | Initiation date: Dec 2019 --> Mar 2020 | Trial primary completion date: Mar 2023 --> Jun 2023
    Clinical • Trial completion date • Trial initiation date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8)
    |
    IDH2 mutation
    |
    rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine